公开(公告)号：US12221433B2

公开(公告)日：2025-02-11

申请号：US17338368

申请日：2021-06-03

Applicant: Unity Biotechnology, Inc.

Inventor： Anne-Marie Beausoleil ,  Ryan Hudson

IPC: C07D401/12 ,  A61P9/10 ,  A61P11/00 ,  A61P27/00 ,  A61P35/00 ,  C07D401/10 ,  C07D401/14 ,  C07D403/10 ,  C07F9/6509

Abstract: The aryl sulfonamide compounds of this invention have powerful and cell-type specific Bcl inhibitory activity. Selected compounds in this class promote apoptosis in senescent cells, and are being developed for treating senescent-related conditions. Selected compounds in this class promote apoptosis in cancer cells, and can be developed as chemotherapeutic agents.

公开(公告)号：US20210169876A1

公开(公告)日：2021-06-10

申请号：US17114379

申请日：2020-12-07

Applicant: Buck Institute for Research on Aging ,  Unity Biotechnology, Inc. ,  Mayo Foundation for Medical Education and Research

Inventor： Remi-Martin Laberge ,  Judith Campisi ,  Marco Demaria ,  Nathaniel David ,  James L. Kirkland ,  Tamar Tchkonia ,  Yi Zhu

IPC: A61K31/496 ,  A61P11/00 ,  A61P9/10 ,  A61P27/02 ,  A61K31/428 ,  A61K31/495 ,  A61K31/5377 ,  C12N15/113 ,  A61P25/28 ,  A61K47/68 ,  A61K31/404 ,  A61K31/4375 ,  A61K45/06 ,  A61K31/4178 ,  A61K31/728 ,  C12N5/00 ,  A61K47/36 ,  A61K9/00

Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

公开(公告)号：US20200253991A1

公开(公告)日：2020-08-13

申请号：US16791960

申请日：2020-02-14

Applicant: Unity Biotechnology, Inc.

Inventor： Pam Tsuruda ,  Jill Hopkins ,  Harry Sweigard ,  Yan Poon ,  Jamie Dananberg ,  Daniel Marquess ,  Nathaniel David

IPC: A61K31/635 ,  A61P27/02

Abstract: This invention is based on the discovery that many eye conditions associated with aging are mediated at least in part by cells bearing a senescent phenotype. Senescent cells accumulate with age, and express factors that contribute to the pathophysiology of age related conditions. The data show that in age-matched patients, the severity of age-related conditions correlates with the abundance of senescent cells, and that clearing senescent cells can help abrogate the condition. Small molecule drugs that remove senescent cells from affected tissue in the eye are provided that have special efficacy in treating ophthalmic conditions. They not only inhibit progression of the disease, they can also reverse some of the pathophysiology—such as neovascularization and vaso-obliteration—that lead to vision loss. These senolytic agents have an appropriate dose and specificity profile to be effective in the clinical management of previously intractable ophthalmic conditions.

公开(公告)号：US20200069703A1

公开(公告)日：2020-03-05

申请号：US16578130

申请日：2019-09-20

Applicant: Unity Biotechnology, Inc.

Inventor： Nathaniel David

IPC: A61K31/575 ,  A61K31/166 ,  A61K31/122 ,  A61K31/11 ,  A61K31/4178 ,  A61K31/138 ,  A61K31/05 ,  A61K31/496 ,  A61K31/433 ,  A61K31/427 ,  A61K31/426 ,  A61K31/4741 ,  A61K31/352 ,  A61K31/4709 ,  A61K31/541 ,  A61K31/167 ,  A61K31/365 ,  A61K31/4025 ,  A61K9/00

Abstract: Disclosed herein are compounds that are effective for treatment of various disease states associated with senescence. The disclosed compounds can be used to eliminate senescent cells for disease treatment. The dosing of the compounds includes both single administration and regimens of cycling dosages.

公开(公告)号：US10517866B2

公开(公告)日：2019-12-31

申请号：US15981696

申请日：2018-05-16

Applicant: Unity Biotechnology, Inc. ,  Buck Institute for Research on Aging ,  Mayo Foundation for Medical Education and Research

Inventor： Remi-Martin Laberge ,  James L. Kirkland ,  Tamar Tchkonia ,  Yi Zhu ,  Nathaniel David ,  Alain Philippe Vasserot ,  Darren J. Baker ,  Bennett G. Childs ,  Jan M. A. van Deursen

IPC: A61P9/10 ,  A61K31/496 ,  A61P11/00 ,  A61P27/02 ,  A61K31/428 ,  A61K31/495 ,  A61K31/5377 ,  A61K31/404 ,  A61K31/4375 ,  A61K45/06 ,  A61K31/4178 ,  A61K31/728 ,  C12N5/00 ,  A61K47/36 ,  A61K9/00 ,  C12Q1/48

Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

公开(公告)号：US20190316109A1

公开(公告)日：2019-10-17

申请号：US16436265

申请日：2019-06-10

Applicant: Unity Biotechnology, Inc. ,  Kythera Biopharmaceuticals, Inc.

Inventor： Serge Lichtsteiner ,  Nathaniel David

IPC: C12N9/50 ,  A61K38/48 ,  C12N15/85

Abstract: Polypeptides, viruses, methods and compositions provided herein are useful for the selective elimination of senescent cells. Method aspects include methods for inducing apoptosis in a senescent cell comprising administering to the cell a polynucleotide, virus, host cell, or pharmaceutical composition described herein. Other methods include expressing a pro-apoptotic gene in a senescent cell comprising administering to the cell the polynucleotide, virus, or pharmaceutical composition as described herein.

公开(公告)号：US10426788B2

公开(公告)日：2019-10-01

申请号：US15915989

申请日：2018-03-08

Applicant: Unity Biotechnology, Inc.

Inventor： Nathaniel David

IPC: A61K31/352 ,  A61K31/575 ,  A61K9/00 ,  A61K31/4025 ,  A61K31/365 ,  A61K31/167 ,  A61K31/541 ,  A61K31/4709 ,  A61K31/4741 ,  A61K31/426 ,  A61K31/427 ,  A61K31/433 ,  A61K31/496 ,  A61K31/05 ,  A61K31/138 ,  A61K31/4178 ,  A61K31/11 ,  A61K31/122 ,  A61K31/166

Abstract: Disclosed herein are compounds that are effective for treatment of various disease states associated with senescence. The disclosed compounds can be used to eliminate senescent cells for disease treatment. The dosing of the compounds includes both single administration and regimens of cycling dosages.

公开(公告)号：US10378002B2

公开(公告)日：2019-08-13

申请号：US16029244

申请日：2018-07-06

Applicant: Unity Biotechnology, Inc. ,  Kythera Biopharmaceuticals, Inc.

Inventor： Serge Lichtsteiner ,  Nathaniel David

IPC: C12N9/50 ,  C12N15/85 ,  A61K38/48

Abstract: Polypeptides, viruses, methods and compositions provided herein are useful for the selective elimination of senescent cells. Method aspects include methods for inducing apoptosis in a senescent cell comprising administering to the cell a polynucleotide, virus, host cell, or pharmaceutical composition described herein. Other methods include expressing a pro-apoptotic gene in a senescent cell comprising administering to the cell the polynucleotide, virus, or pharmaceutical composition as described herein.

公开(公告)号：US20190151337A1

公开(公告)日：2019-05-23

申请号：US16160840

申请日：2018-10-15

Applicant: Unity Biotechnology, Inc. ,  Buck Institute for Research on Aging

Inventor： Pam Tsuruda ,  Jill Hopkins ,  Harry Sweigard ,  Yan Poon ,  Jamie Dananberg ,  Daniel Marquess ,  Nathaniel David

IPC: A61K31/635 ,  A61K9/00 ,  A61P27/02

CPC classification number: A61K31/635 ,  A61K9/0019 ,  A61K9/0048 ,  A61K47/10 ,  A61K47/20 ,  A61K47/26 ,  A61P27/02

Abstract: This invention is based on the discovery that many eye conditions associated with aging are mediated at least in part by cells bearing a senescent phenotype. Senescent cells accumulate with age, and express factors that contribute to the pathophysiology of age related conditions. The data show that in age-matched patients, the severity of age-related conditions correlates with the abundance of senescent cells, and that clearing senescent cells can help abrogate the condition. Small molecule drugs that remove senescent cells from affected tissue in the eye are provided that have special efficacy in treating ophthalmic conditions. They not only inhibit progression of the disease, they can also reverse some of the pathophysiology—such as neovascularization and vaso-obliteration—that lead to vision loss. These senolytic agents have an appropriate dose and specificity profile to be effective in the clinical management of previously intractable ophthalmic conditions.

公开(公告)号：US10195213B2

公开(公告)日：2019-02-05

申请号：US15069769

申请日：2016-03-14

Applicant: Unity Biotechnology, Inc.

Inventor： Nathaniel David

IPC: A61K31/05 ,  A61K31/575 ,  A61K9/00 ,  A61K31/4025 ,  A61K31/365 ,  A61K31/167 ,  A61K31/541 ,  A61K31/4709 ,  A61K31/352 ,  A61K31/4741 ,  A61K31/426 ,  A61K31/427 ,  A61K31/433 ,  A61K31/496 ,  A61K31/138 ,  A61K31/4178 ,  A61K31/11 ,  A61K31/122 ,  A61K31/166

Abstract: Disclosed herein are compounds that are effective for treatment of various disease states associated with senescence. The disclosed compounds can be used to eliminate senescent cells for disease treatment. The dosing of the compounds includes both single administration and regimens of cycling dosages.